Dr Michael Thurn – CEO
Dr Michael Thurn was appointed Chief Executive Officer of Mimetica
in September 2006. Over the last 10 years Dr Thurn has been responsible
for 4 IND-enabling programs and been involved in the preclinical evaluation
of over 12 drugs and vaccines for registration in Australia. Dr Thurn’s
previous appointments include, Managing Director of Spinifex Pharmaceuticals
Pty Ltd, Chief Operating Officer at Cytopia Research Pty Ltd, Head
of Drug Development at Xenome Ltd, Anti-cancer Team Leader at Novogen
Ltd, and Senior Toxicologist at the Therapeutic Goods Administration
(TGA). Dr Thurn obtained his Ph.D in Immunology and Biochemistry from
the University of Technology, Sydney in 1994.
Dr Mark Blaskovich – COO
An experienced industrial medicinal chemist, Mark has worked for CEPTYR
Inc and the former peptide mimetics company Molecumetics. He is an
effective team leader with proven project management and partner collaboration
skills. Extensive organic synthesis expertise with both solution phase
and solid phase methods and experience managing project outcomes with
ADME, analytical, computational modeling and biology experts.
Nicholas Peace – Director
Nick Peace joined Starfish Ventures in May
2002, focusing on early stage life and materials science investments.
His role includes identification and evaluation of prospective investments,
execution of new portfolio investments and ongoing monitoring of investee
companies. Prior to joining Starfish Ventures, Nick worked as a corporate
lawyer in Melbourne at Freehills and subsequently in London at Mayer
Brown Rowe & Maw,
specializing in mergers and acquisitions and private equity transactions
in sectors ranging from telecommunications to specialty chemicals.
Nick holds a Bachelor of Laws (Hons) and a Bachelor of Science from
the University of Melbourne and a Master of Business Administration
from INSEAD.
Stephen Robinson – Director
Stephen Robinson has been an executive director of Start-up Australia
Ventures Pty Limited Australia since 1997. Start-up Australia is a
venture capital group specialising in early stage biotechnology investments.
He has been involved in the venture capital industry since 1994. He
is also a director of Protagonist Pty Limited, Caldeon Pty Limited
and Replikun Biotech Pty Limited. Stephen holds a Bachelor of Commerce
(B.Com) with merit from the University of New South Wales and a Master
of Business Administration (MBA) from Macquarie Graduate School of
Management. He is a member of The Institute of Chartered Accountants
in Australia (CA).
|
